Compare · BRVE vs NVS
BRVE vs NVS
Side-by-side comparison of Braveheart Bio Inc. (BRVE) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRVE and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $287.12B, about 156.7x BRVE ($1.83B).
- Over the past year, BRVE is down 33.1% and NVS is up 18.2% - NVS leads by 51.3 points.
- BRVE has been more active in the news (10 items in the past 4 weeks vs 6 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 0 for BRVE).
- Company
- Braveheart Bio Inc.
- Novartis AG
- Price
- $20.41+6.05%
- $150.47-0.50%
- Market cap
- $1.83B
- $287.12B
- 1M return
- -4.69%
- -3.71%
- 1Y return
- -33.08%
- +18.20%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 10
- 6
- Recent ratings
- 0
- 25
Braveheart Bio Inc.
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ('HCM') and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non-obstructive HCM. Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity. BHB-1893 was initially discovered and developed by Jiangsu Hengrui Pharmaceuticals Co in China. We in-licensed BHB-1893 pursuant to an exclusive license agreement with Hengrui.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest BRVE
- SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.
- SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.
- SEC Form 10-Q filed by Braveheart Bio Inc.
- Braveheart Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
- Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
- SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.
- Braveheart Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
- SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG